期刊文献+

探讨肺栓塞致右心功能不全的治疗

Discussion of Therapy of Right Ventricular Dysfunction Caused by Pulmonary Embolism
暂未订购
导出
摘要 目的探索肺栓塞致右心功能不全患者的治疗方案,为临床提供治疗依据。方法依据用药的不同将确诊的60例肺栓塞致右心功能不全患者分为四组,尿激酶组(Ⅰ组)、重组组织型纤溶酶原激活剂(rt-PA)组(Ⅱ组)、尿激酶与西地那非合用组(Ⅲ组)、rt-PA与西地那非合用组(Ⅳ组),每组各15例。疗程为1周,观察各组患者治疗前后的临床表现及以下指标:平均肺动脉压力(mPAP)、右心室舒张末期内径(RVD)、三尖瓣反流压差(PGTI)、D-二聚体(D-D)、动脉血氧分压(PO2)、二氧化碳分压(PCO2)。结果四组患者的临床表现均明显缓解,mPAP、RVD、PGTI、D-D、PO2、PCO2均较治疗前改善(P<0.05)。治疗后各组间比较,mPAP、RVD、PGTI差异有统计学意义(P<0.05),D-D、PO2、PCO2差异无统计学意义(P>0.05),Ⅳ组mPAP、RVD、PGTI下降最明显。结论溶栓、抗凝治疗是肺栓塞致右心功能不全的根本治疗方案,溶栓联合降肺动脉高压治疗疗效显著,rt-PA联合西地那非治疗疗效尤为显著,值得临床推广。 Objective To explore the different treatment regimes to patientswith right ventricular dysfunction induced by pulmonary embolism.Methods 60 patients with right ventricular dysfunction induced by pulmonary embolism were divided into four groups,namely the urokinase group(group Ⅰ);recombinant tissue type plasminogen activator(rt-PA)group(group Ⅱ);urokinase and sildenafil in the combination group(group Ⅲ);rt-PA and sildenafil in the combination group(group Ⅳ),15 cases in each group.After 1 week of treatment,the clinical manifestation and the following indicators were observed:mean pulmonary artery pressure(mPAP),right ventricular end-diastolic inner diameter(RVD),pressure gradient of tricuspid valve regurgitation(PGTI),D-dimers(D-D),partial pressure of oxygen(PO2),pressure of carbon dioxide(PCO2).Results The clinical manifestations of the four groups were significantly relieved,mPAP,RVD,PGTI,D-D,PO2,PCO2 were improved(P〈0.05).After treatment,the differences of mPAP,RVD and PGTI were statistically significant among the four groups(P〈0.05).D-D,PO2,PCO2 had no significant difference(P〈0.05).mPAP,RVD and PGTI of the Ⅳ group were most obviously decreased.Conclusion To patients with right ventricular dysfunction induced pulmonary embolism,thrombolysis and anticoagulation therapy are theradical therapies,the curative effect of thrombolysis combined with reducing pulmonary arterial hypertension is significant,among which rt-PA combined with sildenafil is particularly significant,worthy of clinical promotion.
出处 《医学综述》 2012年第9期1415-1417,共3页 Medical Recapitulate
关键词 肺栓塞 右心功能不全 尿激酶 重组组织型纤溶酶原激活剂 西地那非 Pulmonary embolism Right ventricular dysfunction Urokinase Recombinant tissue type plasminogen activator Sildenafil
  • 相关文献

参考文献10

  • 1Torbicki A, Perrier A, Konstantinides S ,et al. Guidelines on the di- agnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Em- bolism of the European Society of Cardiology(ESC) [ J ]. Eur Heart J.2008.29( 18 ) ,2276-2315.
  • 2胡大一,冯新庆.提高对肺栓塞的识别能力和诊断水平[J].中华医学杂志,2001,81(24):1479-1480. 被引量:18
  • 3Barst R], Megoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension [ J ]. J Am Coil Car- diol,2004,43 (12 Suppl S) :40S-47S.
  • 4Contractor S, Maldjian PD, Sharma VK,et al. Role of helical CT in detecting right ventricular dysfunction secondary to acute pulmona- ry embolism [ J ]. J Comput Assist Tomogr, 2002,26 (4) :587 -591.
  • 5陆卫华,唐忠志,马毅,余志华.溶栓加抗凝疗法与单纯抗凝疗法对次大面积肺栓塞的疗效及远期预后的影响[J].临床军医杂志,2008,36(3):340-342. 被引量:35
  • 6荆志成,徐希奇.静脉血栓栓塞症流行病学及危险因素概览[N].中国医学论坛报,2009-11-26(C2).
  • 7Ouriel K, Gray B, Clair DG, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis [J]. J Vasc Interv Radiol,2000,11 (3) :295-298.
  • 8Goldhaber SZ,Kessler CM,Hcit J,et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism [ J ]. Lancet, 1988,2 (8606) : 293 -298.
  • 9Aldashev AA, Kojonazarov BK, Amatov TA, et al. Phosphodiester- ase type 5 and high altitude pulmonary hypertension [ J ]. Thorax, 2005,60 ( 8 ) :683-687.
  • 10Archer SL, Michelakis ED. Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension [ J ]. N Engl J Med ,2009 ,361 ( 19 ) : 1864-1871.

二级参考文献5

共引文献54

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部